Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
Publication/Presentation Date
1-1-2019
Abstract
Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, and that such genomic aberrations are synthetically lethal with both poly(ADP)-ribose polymerase inhibition and platinum, has increased interest in the utilisation of these drugs against a subset of these diseases. Here in we report three patients with advanced castration-resistant PCa with HRD defects having exceptional responses to carboplatin.
Volume
75
Issue
1
First Page
184
Last Page
192
ISSN
1873-7560
Published In/Presented At
Zafeiriou, Z., Bianchini, D., Chandler, R., Rescigno, P., Yuan, W., Carreira, S., Barrero, M., Petremolo, A., Miranda, S., Riisnaes, R., Rodrigues, D. N., Gurel, B., Sumanasuriya, S., Paschalis, A., Sharp, A., Mateo, J., Tunariu, N., Chinnaiyan, A. M., Pritchard, C. C., Kelly, K., … de Bono, J. S. (2019). Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. European urology, 75(1), 184–192. https://doi.org/10.1016/j.eururo.2018.09.048
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
30340782
Department(s)
Administration and Leadership
Document Type
Article